Key Drivers
- Profitability Strong
- Liquidity Healthy
- Bounce intact
AIAI Summary
Agilent is evolving from a steady, high-quality tools name into a broader growth story via Biocare, product launches, and AI-enabled workflows, but at ~30x earnings the stock needs clear execution and a China/academic demand recovery to justify upside, making this a quality holding best bought on pullbacks rather than chased here.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Strong
- •Liquidity Healthy
A shows strong profitability, cash generation, and liquidity with manageable leverage, but its premium valuation and heavy intangible asset base limit margin of safety.
Valuation: The shares look expensive relative to fundamentals, making the current setup more quality-driven than value-driven.
Price Behavior
Key Price Behavior Insights:
- •Bounce intact
- •Momentum faded
- •Mid-$130s cap
A remains choppy and only cautiously constructive after rebounding from mid-June lows, but failure to reclaim and hold the mid-$130s leaves the recovery vulnerable.
Sharp rebound from $124.09 on 2026-06-17 to $135.75 on 2026-06-26, then slipped back to $130.69 by 2026-07-02
Sentiment & News
Key News Insights:
- •Agilent Acquisition
- •Class-Action Overhang
- •Event-Driven Catalysts
Agilent's completed Biocare Medical acquisition stands out in a news flow otherwise dominated by class-action deadlines, deal activity, and earnings/event calendar updates, signaling mixed but mostly headline-driven sentiment. #M&A
The news flow suggests limited near-term operating catalysts, with litigation risk and transaction headlines likely to keep sentiment choppy for the instrument
Similar Companies in Healthcare
Other companies in the same sector with AI ratings